

# General Regulatory Update

**Paul Sexton**

**GMP Policy Manager**

---

**QP Forum – May 13<sup>th</sup> 2025**




## Current Regulatory Topics (Interested Parties)

Annual Meeting of Inspectors Working Group with Interested Parties


Interested Parties include representative bodies for:

- Human medicines
- Veterinary medicines
- Qualified Persons

Meeting took place during March 2025



## GMDP IWG Meetings in 2024




*Courtesy of EMA*



## MRAs

- **Expansion of scope to include veterinary medicines in the operational scope of the EU – US Mutual Recognition Agreement**
  - Work continued on the inclusion of veterinary medicines in the operational scope with 3 authorities currently pending
  - The current [list of recognised authorities](#) for the veterinary scope is published by the European Commission
  - Batch testing waiving would only start to apply when all EU veterinary authorities have been recognised by the US
- **Consideration of inclusion of vaccines and plasma derived products (PDP)**
  - Work on-going (EU inspectors observed 2 FDA PDP inspections in the EU in 2024)

*Courtesy of EMA*



## GMP certificate

### ➤ Automatic Extension

- Employed during Covid-19 pandemic
- Back to normal scheduling and conduct of on-site inspections
- Blanket approach no longer required
- Automatic extension finished in December 2024
- Case by case assessment when required for certain sites
- On site inspection is the primary means of verification of compliance
- Other tools : Distant assessments, Hybrid inspections, Reliance on other authorities



# GMP Guidance

**Annex 11** and **Chapter 4** drafting group in progress with expected guidelines to be published for consultation in 2025

**Annexes 4** and **5** in progress

## **Annex 19**

IWG adopted revision on reference and retention samples for Parallel Distribution/Importation, currently for publication

Revisions of **Annexes 3, 6, 15** new drafting groups started


Started a *targeted revision* on the **Guideline on GMP for ATMPs** (to align with Annex 1 revision)

Formed the IWG **Drafting Group on Good Distribution Practice**

## **Q&As & Guidance**

- Q&A on Annex 1
- Q&A on Suspicious offers for Wholesalers and Brokers
- Q&A on Annex 14 concerning APIs derived from human plasma
- Q&A on Annex 16 concerning traceability of the supply chain for QP batch release.
- Distant Assessment Guidance

*Courtesy of EMA*



## Veterinary Implementing Regulations

- COMMISSION IMPLEMENTING REGULATION (EU) .../... of XXX laying down good manufacturing practice for veterinary medicinal products in accordance with Regulation (EU) 2019/6 of the European Parliament and of the Council
- [https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/13994-Veterinary-medicines-rules-on-good-manufacturing-practices\\_en](https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/13994-Veterinary-medicines-rules-on-good-manufacturing-practices_en)
- COMMISSION IMPLEMENTING REGULATION (EU) .../... of XXX laying down good manufacturing practice for active substances used as starting materials in veterinary medicinal products in accordance with Regulation (EU) 2019/6 of the European Parliament and of the Council
- [https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/14388-Veterinary-medicines-rules-on-good-manufacturing-practices-for-active-substances-used-as-starting-materials\\_en](https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/14388-Veterinary-medicines-rules-on-good-manufacturing-practices-for-active-substances-used-as-starting-materials_en)
- Short public consultation 22<sup>nd</sup> January – 19<sup>th</sup> February 2025
- Text finalised and now awaiting translation / publication in the Official Journal



## Veterinary Implementing Regulations

- Different structure to the current GMP Guide
- Reflect specific GMP requirements
- Legal text (uses **shall** instead of **should**)
- Largely aligned with GMP requirements for human medicines (except vet specific aspects)
- Implementing Regulations will be changed as needed





## Revision of Pharma Legislation concerning Human Medicines

**New Directive** - (Directive 2001/83/EC to be repealed)

**New Regulation** – (Regulation No 726/2004 to be repealed)

### Some topics

- Decentralised Manufacturing
- Aspects related to QP
- Financial importation
- Inspections – (proposal for EMA inspectorate)

Proposal for GMP / GDP requirements within Implementing Acts




# Compilation of Union Procedures & EudraGMDP

**Compilation of Union Procedures on Inspections and Exchange of Information (CoUP) restructured from one document into separate documents for every procedure/template**

**EudraGMDP database**

*Restructuring to facilitate access as well as review and revision of the individual documents*

*Several minor changes have been implemented in EudraGMDP modules*




## EudraGMDP – support to Industry Stakeholders

### EMA communication channels

- **IT issues/technical questions** on **EudraGMDP** should be raised via [ServiceNow](#), the new EMA Service Desk platform
- Issues related to the data in **OMS** should be raised via [SPOR](#)
- **Regulatory questions** via [AskEMA](#)

### HPRA communication channels

- Queries relating to content of documents issued by the HPRA on EudraGMDP (e.g. MIAs, GMP Certs, ASR, WDA, GDP certs) should be addressed to [compliance@hpra.ie](mailto:compliance@hpra.ie)




# Interested Parties Topics

## Revision of ICH Q9 (R1)

- Some consequential targeted revisions of text in GMP Guide


Chapter 1 - Pharmaceutical Quality System

Annex 15 - Qualification and Validation



## Revision of Part IV GMP for ATMP

- Concept Paper published
- Consultation Period 8<sup>th</sup> May – 8<sup>th</sup> July 2025
- Focus on alignment with revised Annex 1 while maintaining flexible approach
  - Use of ICHQ9 & ICHQ10
  - Concept of Contamination Control Strategy
  - New technologies for manufacture of ATMPs (automation, single use systems, rapid micro)
  - Qualification and management of cleanrooms
  - Guidance on use of RABS & Isolators whilst still facilitating use of BSCs



## International collaboration

**Support for  
candidate  
countries for EU  
Accession**

**Support for the development of the African Medicines Agency**

**Close  
collaboration with  
PIC/s on  
guidelines and  
inspector training**

Observers from  
Albania, Bosnia and  
Herzegovina, Georgia,  
Kosovo, Moldova,  
Montenegro, North  
Macedonia, Serbia,  
Turkiye and Ukraine  
attended GMDP IWG  
meetings throughout  
2024

Support with GMP  
Training

Delegation of the  
African Medicines  
Regulatory  
Harmonisation  
Initiative GMP Technical  
Committee (AMRH  
GMP TC) observed part  
of the June 2024  
plenary meeting

EMA Liaison to the  
AMRH GMP TC

**Continued work  
under the  
established  
international  
collaboration  
schemes for API  
Inspection  
programme and  
the ICMRA Hybrid  
Inspection Pilot**

*Courtesy of EMA*

# Thank You

**Acknowledgement: Andrei Spinei,**  
Manufacturing Team Lead  
Inspections Office  
EMA